Virosome Platform Licensing Mymetics offers a virosome-based vaccine platform backed by partnerships with Astellas Pharma, PATH-MVI and the Gates Foundation, creating opportunities to license the platform to pharmaceutical developers or researchers for new infectious disease vaccines and mucosal applications.

Thermostable Vaccine Edge The company's focus on thermostable and cold-chain independent vaccines since 2015 aligns with global access needs, presenting sales opportunities for formulation support, development services, and partnerships with organizations pursuing vaccines for resource-limited settings.

Nasal Delivery Collaboration Recent Therakind integration demonstrates the potential to co-develop or supply integrated nasal vaccine solutions that combine virosome-based antigens with intranasal delivery devices, including regulatory and development support.

Global Health Funding With established ties to Gates Foundation and PATH-MVI, there are pathways to win grant-funded development programs, enabling project-based R&D, validation studies, and scale-up planning for widespread immunization initiatives.

Strategic Partnerships & CROs A Swiss base with a Netherlands lab and a lean team size makes Mymetics a strong partner for collaboration with larger pharma or CRO networks, offering joint research, contract development, and potential manufacturing collaboration leveraging existing relationships.